Alessandra Tedeschi
Overview
Explore the profile of Alessandra Tedeschi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
4280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paludo J, Abeykoon J, Perera N, Sarosiek S, Gustine J, Ramirez-Gamero A, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062689
As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However,...
2.
Frustaci A, Zappaterra A, Galitzia A, Visentin A, Merli M, Rizzi R, et al.
Hemasphere
. 2025 Feb;
9(2):e70094.
PMID: 39981189
No abstract available.
3.
Brown J, Seymour J, Jurczak W, Aw A, Wach M, Illes A, et al.
N Engl J Med
. 2025 Feb;
392(8):748-762.
PMID: 39976417
Background: Whether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. Methods: In this phase...
4.
Innocenti I, Tomasso A, Giannarelli D, Scarfo L, Murru R, Visentin A, et al.
Hematol Oncol
. 2025 Jan;
43(1):e70033.
PMID: 39809722
No abstract available.
5.
Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, et al.
J Clin Oncol
. 2024 Dec;
43(7):780-787.
PMID: 39647999
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with...
6.
Heyman B, Opat S, Wahlin B, Dimopoulos M, Dimopoulos M, Castillo J, et al.
Blood Adv
. 2024 Dec;
9(4):722-728.
PMID: 39626287
Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients...
7.
Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfo L, Morelli F, et al.
Hemasphere
. 2024 Dec;
8(12):e144.
PMID: 39619246
No abstract available.
8.
Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, et al.
Blood Adv
. 2024 Oct;
9(1):162-165.
PMID: 39454205
No abstract available.
9.
Tedeschi A, Frustaci A, Condoluci A, Coscia M, Chiarle R, Zinzani P, et al.
Lancet Oncol
. 2024 Sep;
25(10):1298-1309.
PMID: 39270702
Background: The diffuse large B-cell lymphoma (DLBCL) variant of Richter transformation (DLBCL-RT) is typically chemoresistant with poor prognosis. Aiming to explore a chemotherapy-free treatment combination that triggers anti-tumour immune responses,...
10.
Deodato M, Frustaci A, Zappaterra A, Rapella A, Gambacorti-Passerini C, Cairoli R, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2096-2107.
PMID: 39219481
Richter's transformation (RT) is defined as the evolution of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. This complication...